[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-386991-105":59,"doc-detail-386991-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","acetylsalicylic-acid-asa-objective-background-mechanism-indications-dosing-and-adverse-effects","Acetylsalicylic Acid (ASA) - Objective, Background, Mechanism, Indications, Dosing and Adverse Effects","","Acetylsalicylic Acid (ASA) information focuses on preventing vascular thromboembolic events by outlining its role in acute myocardial infarction, secondary prevention of cardiovascular disease, and selected prevention of recurrent venous thromboembolism (VTE) and VTE after joint arthroplasty. The document explains ASA’s irreversible inhibition of platelet aggregation via thromboxane A2 (TxA2) suppression, summarizes key indications across cardiac, cerebrovascular, and peripheral arterial disease, and clarifies when primary prevention is not routinely recommended. Dosing guidance includes standard and initial loading regimens for ACS, prior angioplasty, and TIA or noncardioembolic stroke, alongside considerations for gastrointestinal bleeding risk and common adverse effects such as bruising and dyspepsia.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/acetylsalicylic-acid-asa-objective-background-mechanism-indications-dosing-and-adverse-effects/386991/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/acetylsalicylic-acid-asa-objective-background-mechanism-indications-dosing-and-adverse-effects/386991.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of using acetylsalicylic acid (ASA) in this document?","Question",{"text":113,"@type":114},"The objective is to provide information on ASA’s use to prevent vascular thromboembolic events.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does ASA work according to the mechanism of action section?",{"text":118,"@type":114},"ASA irreversibly inhibits platelet aggregation by inhibiting thromboxane A2 (TxA2) synthesis.",{"name":120,"@type":111,"acceptedAnswer":121},"What dosing guidance is provided for common situations such as ACS and angioplasty?",{"text":122,"@type":114},"A usual anti-platelet dose is 81 mg daily, with a single initial 162 mg chew/crush dose for ACS followed by indefinite 81 mg daily, and a single initial 325 mg chew/crush dose prior to angioplasty if not already on chronic daily ASA.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},386991,1790449721,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Acetylsalicylic Acid (ASA)  \nObjective:  \nTo provide information on the use of acetyl salicylic acid in the prevention of vascular thromb oembolicevents.  \nBackground:  \nAcetyl salicylic acid (ASA) is well-established in the management of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women, based on large randomized trials. ASA may also be considered in selected patients for prevention of recurrent venous thromboembolism (VTE) and for prevention of VTE following joint arthroplasty. In addition, in select patients with sub clinical vascular disease, ASA may be considered for primary prevention of cardiovascular events. The net benefit of ASA use depends on weighing the anticipated reduction in cardiovascular events against the increased risk of gastrointestinal and intracranial bleeding.  \nMechanism of Action:  \nASA irreversibly inhibits platelet aggregation by inhibiting thromboxane A2 (TxA2) synthesis.  \nIndications:  \n( Unless otherwise indicated, ASA refers to enteric-coated ASA)  \nAnti platelet therapy with ASA is recommended for all patients with the following, unless contraindicated:  \nCardiac: For all patients with symptomatic coronary artery disease (CAD), including:  \n1. History of acute coronary syndrome (ACS) with and without ST segment elevation  \n2. Chronic stable angina  \n3. Following percutaneous coronary intervention ( PCI) or coronary artery bypass graft (CABG)  \n In combination with clopidogrel (elective PCI), prasugrel, or ticagrelor ( PCI for ACS) while the patient remains at very high risk for subsequent coronary events (usually one year)[ see Clinical Guide: Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease]  \n In combination with clopidogrel and oral anti coagulation in patients with an indication for anti coagulation, for the shortest possible duration, while the patient is at extremely high risk for subsequent coronary events [ see Clinical Guide: Anticoagulation in Patients Requiring Antiplatelet Therapy] .  \n4. May be considered in combination with rivaroxaban 2.5 mg twice daily for patients with coronary artery disease or peripheral artery disease for prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality [ see Clinical Guide: Rivaroxaban (Xarelto®)  \n5. Prosthetic heart valves:  \n ASA 81 mg daily is recommended in addition to vitamin K antagonist (VKA) in selected high-risk patients with a mechanical valve prosthesis (see Clinical Guide: Mechanical and Bioprosthetic Heart Valves: Anticoagulant Therapy)  \n ASA 81 mg daily is reasonable in all patients with a bioprosthetic aortic or mitral valve who are not taking an oral anticoagulant (see Clinical Guide: Mechanical and Bioprosthetic Heart Valves: Anticoagulant Therapy)  \nCerebrovascular:  \n For patients with history of non-cardioembolic ischemic stroke or transient ischemic attack (TIA) [ see Clinical Guide: Stroke: Secondary Prevention]  \n Following carotid end arterectomy  \nPeripheral arterial disease (PAD):  \n Symptomatic patients with or without a history of vascular intervention [ see Clinical Guide: Peripheral Arterial Disease]  \nPrimary prevention of cardiovascular morbidity and mortality:  \nThe use of ASA is not routinely recommended for primary prevention of a first vascular event.  \n This recommendation pertains to individuals with or without vascular risk factors who have not had avascular event.  \n The net benefit of ASA in individuals with asymptomatic atherosclerosis (i. e. asymptomatic coronary or carotid atherosclerosis) is uncertain.  \nSecondary prevention of recurrent VTE:  \n In patients at high risk of VTE recurrence following completion of initial anticoagulant therapy for a minimum of 3-6 months, ASA may be considered as an option to decrease recurrent VTE only if extended anticoagulant therapy is not acceptable to the patient. [ see Clinical Guide: Venous Thromboembolis","cbCaifpczKg3prVT","https://ap.wps.com/l/cbCaifpczKg3prVT","pdf",318006,"English","# Objective\n# Background\n# Mechanism of Action\n# Indications\n## Cardiac indications\n## Cerebrovascular and peripheral arterial disease\n## VTE and orthopedic thromboprophylaxis\n## Pregnancy preeclampsia prevention\n# Dosing\n# Adverse Effects","[{\"question\":\"What is the main objective of using acetylsalicylic acid (ASA) in this document?\",\"answer\":\"The objective is to provide information on ASA’s use to prevent vascular thromboembolic events.\"},{\"question\":\"How does ASA work according to the mechanism of action section?\",\"answer\":\"ASA irreversibly inhibits platelet aggregation by inhibiting thromboxane A2 (TxA2) synthesis.\"},{\"question\":\"What dosing guidance is provided for common situations such as ACS and angioplasty?\",\"answer\":\"A usual anti-platelet dose is 81 mg daily, with a single initial 162 mg chew/crush dose for ACS followed by indefinite 81 mg daily, and a single initial 325 mg chew/crush dose prior to angioplasty if not already on chronic daily ASA.\"}]","Acetylsalicylic Acid (ASA) - Objective, Background, Mechanism, Indications, Dosing and Adverse Effects | PDF",1790280337,15]